Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research
Abstract There has been a surge in the emergence of HIV-1 drug resistance in Low and Middle-Income Countries (LMICs) due to poor drug-adherence and limited access to viral load testing, the current standard for treatment-monitoring. It is estimated that only 75% of people living with HIV (PLWH) worl...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-03-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-31103-y |
| _version_ | 1797865038931820544 |
|---|---|
| author | Jemima Malisa Mark Manak Clive Michelo Nesrina Imami Catherine N. Kibirige |
| author_facet | Jemima Malisa Mark Manak Clive Michelo Nesrina Imami Catherine N. Kibirige |
| author_sort | Jemima Malisa |
| collection | DOAJ |
| description | Abstract There has been a surge in the emergence of HIV-1 drug resistance in Low and Middle-Income Countries (LMICs) due to poor drug-adherence and limited access to viral load testing, the current standard for treatment-monitoring. It is estimated that only 75% of people living with HIV (PLWH) worldwide have access to viral load testing. In LMICs, this figure is below 50%. In a recent WHO survey in mostly LMICs, 21 out of 30 countries surveyed found HIV-1 first-line pre-treatment drug resistance in over 10% of study participants. In the worst-affected regions, up to 68% of infants born to HIV-1 positive mothers were found to harbour first-line HIV-1 treatment resistance. This is a huge public health concern. Greater access to treatment-monitoring is required in LMICs if the UNAIDS “third 95” targets are to be achieved by 2030. Here, we review the current challenges of viral load testing and present the case for greater utilization of Laboratory-based assays that quantify intracellular HIV-1 RNA and/or DNA to provide broader worldwide access to HIV-1 surveillance, drug-resistance monitoring, and cure-research. |
| first_indexed | 2024-04-09T23:02:42Z |
| format | Article |
| id | doaj.art-401bb5d2b4bb44809d8a2164adf53dbd |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-09T23:02:42Z |
| publishDate | 2023-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-401bb5d2b4bb44809d8a2164adf53dbd2023-03-22T10:53:57ZengNature PortfolioScientific Reports2045-23222023-03-011311710.1038/s41598-023-31103-yUse of laboratory-developed assays in global HIV-1 treatment-monitoring and researchJemima Malisa0Mark Manak1Clive Michelo2Nesrina Imami3Catherine N. Kibirige4IAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation TrustTuresol ConsultingZambia Emory HIV Research ProjectCentre for Immunology and Vaccinology, Imperial College London, Chelsea and Westminster NHS Foundation TrustIAVI, Human Immunology Laboratory, Imperial College London, Chelsea and Westminster NHS Foundation TrustAbstract There has been a surge in the emergence of HIV-1 drug resistance in Low and Middle-Income Countries (LMICs) due to poor drug-adherence and limited access to viral load testing, the current standard for treatment-monitoring. It is estimated that only 75% of people living with HIV (PLWH) worldwide have access to viral load testing. In LMICs, this figure is below 50%. In a recent WHO survey in mostly LMICs, 21 out of 30 countries surveyed found HIV-1 first-line pre-treatment drug resistance in over 10% of study participants. In the worst-affected regions, up to 68% of infants born to HIV-1 positive mothers were found to harbour first-line HIV-1 treatment resistance. This is a huge public health concern. Greater access to treatment-monitoring is required in LMICs if the UNAIDS “third 95” targets are to be achieved by 2030. Here, we review the current challenges of viral load testing and present the case for greater utilization of Laboratory-based assays that quantify intracellular HIV-1 RNA and/or DNA to provide broader worldwide access to HIV-1 surveillance, drug-resistance monitoring, and cure-research.https://doi.org/10.1038/s41598-023-31103-y |
| spellingShingle | Jemima Malisa Mark Manak Clive Michelo Nesrina Imami Catherine N. Kibirige Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research Scientific Reports |
| title | Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research |
| title_full | Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research |
| title_fullStr | Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research |
| title_full_unstemmed | Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research |
| title_short | Use of laboratory-developed assays in global HIV-1 treatment-monitoring and research |
| title_sort | use of laboratory developed assays in global hiv 1 treatment monitoring and research |
| url | https://doi.org/10.1038/s41598-023-31103-y |
| work_keys_str_mv | AT jemimamalisa useoflaboratorydevelopedassaysinglobalhiv1treatmentmonitoringandresearch AT markmanak useoflaboratorydevelopedassaysinglobalhiv1treatmentmonitoringandresearch AT clivemichelo useoflaboratorydevelopedassaysinglobalhiv1treatmentmonitoringandresearch AT nesrinaimami useoflaboratorydevelopedassaysinglobalhiv1treatmentmonitoringandresearch AT catherinenkibirige useoflaboratorydevelopedassaysinglobalhiv1treatmentmonitoringandresearch |